{"id":"https://openalex.org/W2093743385","doi":"https://doi.org/10.1089/jwh.2011.2764","title":"The Effect of Dose Titration and Dose Tapering on the Tolerability of Desvenlafaxine in Women with Vasomotor Symptoms Associated with Menopause","display_name":"The Effect of Dose Titration and Dose Tapering on the Tolerability of Desvenlafaxine in Women with Vasomotor Symptoms Associated with Menopause","publication_year":2011,"publication_date":"2011-10-27","ids":{"openalex":"https://openalex.org/W2093743385","doi":"https://doi.org/10.1089/jwh.2011.2764","mag":"2093743385","pmid":"https://pubmed.ncbi.nlm.nih.gov/22032759"},"language":"en","primary_location":{"id":"doi:10.1089/jwh.2011.2764","doi":"https://doi.org/10.1089/jwh.2011.2764","is_oa":false,"landing_page_url":"https://doi.org/10.1089/jwh.2011.2764","pdf_url":null,"source":{"id":"https://openalex.org/S191117624","display_name":"Journal of Women s Health","issn_l":"1059-7115","issn":["1059-7115","1540-9996","1931-843X","2168-7668"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320443","host_organization_name":"Mary Ann Liebert, Inc.","host_organization_lineage":["https://openalex.org/P4310320443","https://openalex.org/P4310320017"],"host_organization_lineage_names":["Mary Ann Liebert, Inc.","SAGE Publishing"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Women's Health","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5037448661","display_name":"John Christopher Gallagher","orcid":"https://orcid.org/0000-0002-5129-9183","observed_orcids":["https://orcid.org/0000-0002-5129-9183"]},"institutions":[{"id":"https://openalex.org/I2800482329","display_name":"CHI Health Creighton University Medical Center - Bergan Mercy","ror":"https://ror.org/03z1w3b90","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2800482329","https://openalex.org/I2802665030","https://openalex.org/I2802797007"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"J. Christopher Gallagher","raw_affiliation_strings":["Creighton University Medical Center, Omaha, Nebraska"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Creighton University Medical Center, Omaha, Nebraska","institution_ids":["https://openalex.org/I2800482329"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5073358999","display_name":"Robert A. Strzinek","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Robert A. Strzinek","raw_affiliation_strings":["Protenium Clinical Research, LLC, Hurst, Texas"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Protenium Clinical Research, LLC, Hurst, Texas","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5047945816","display_name":"Ru-fong Joanne Cheng","orcid":"https://orcid.org/0000-0003-2564-0947","observed_orcids":["https://orcid.org/0000-0003-2564-0947"]},"institutions":[{"id":"https://openalex.org/I4403928396","display_name":"Wyeth","ror":"https://ror.org/035j24j42","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899","https://openalex.org/I4403928396"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ru-fong J. Cheng","raw_affiliation_strings":["Pfizer Inc (formerly Wyeth Research, Collegeville, Pennsylvania), Collegeville, Pennsylvania"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer Inc (formerly Wyeth Research, Collegeville, Pennsylvania), Collegeville, Pennsylvania","institution_ids":["https://openalex.org/I4403928396"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5007054703","display_name":"Militza K. Ausmanas","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4403928396","display_name":"Wyeth","ror":"https://ror.org/035j24j42","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899","https://openalex.org/I4403928396"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Militza K. Ausmanas","raw_affiliation_strings":["Pfizer Inc (formerly Wyeth Research, Collegeville, Pennsylvania), Collegeville, Pennsylvania","Western Institutional Review Board (IRB), Olympia, Washington"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer Inc (formerly Wyeth Research, Collegeville, Pennsylvania), Collegeville, Pennsylvania","institution_ids":["https://openalex.org/I4403928396"]},{"raw_affiliation_string":"Western Institutional Review Board (IRB), Olympia, Washington","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5032523633","display_name":"Dorothea Astl","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4403928396","display_name":"Wyeth","ror":"https://ror.org/035j24j42","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899","https://openalex.org/I4403928396"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Dorothea Astl","raw_affiliation_strings":["Pfizer Inc (formerly Wyeth Research, Collegeville, Pennsylvania), Collegeville, Pennsylvania"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer Inc (formerly Wyeth Research, Collegeville, Pennsylvania), Collegeville, Pennsylvania","institution_ids":["https://openalex.org/I4403928396"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5042469565","display_name":"Palma Seljan","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4403928396","display_name":"Wyeth","ror":"https://ror.org/035j24j42","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899","https://openalex.org/I4403928396"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Palma Seljan","raw_affiliation_strings":["Pfizer Inc (formerly Wyeth Research, Collegeville, Pennsylvania), Collegeville, Pennsylvania"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer Inc (formerly Wyeth Research, Collegeville, Pennsylvania), Collegeville, Pennsylvania","institution_ids":["https://openalex.org/I4403928396"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5037448661"],"corresponding_institution_ids":["https://openalex.org/I2800482329"],"apc_list":null,"apc_paid":null,"fwci":1.5716,"has_fulltext":false,"cited_by_count":21,"citation_normalized_percentile":{"value":0.83498677,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":90,"max":97},"biblio":{"volume":"21","issue":"2","first_page":"188","last_page":"198"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10694","display_name":"Menopause: Health Impacts and Treatments","score":0.9833999872207642,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10694","display_name":"Menopause: Health Impacts and Treatments","score":0.9833999872207642,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10459","display_name":"Sexual function and dysfunction studies","score":0.001500000013038516,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10600","display_name":"Reproductive Health and Contraception","score":0.0006000000284984708,"subfield":{"id":"https://openalex.org/subfields/2739","display_name":"Public Health, Environmental and Occupational Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/desvenlafaxine","display_name":"desvenlafaxine","score":0.9860000014305115},{"id":"https://openalex.org/keywords/dose-titration","display_name":"dose titration","score":0.8949999809265137},{"id":"https://openalex.org/keywords/dose-tapering","display_name":"dose tapering","score":0.9959999918937683},{"id":"https://openalex.org/keywords/vasomotor-symptoms","display_name":"vasomotor symptoms","score":0.7850000262260437},{"id":"https://openalex.org/keywords/menopause","display_name":"menopause","score":0.9549999833106995},{"id":"https://openalex.org/keywords/postmenopausal-women","display_name":"postmenopausal women","score":0.8859999775886536},{"id":"https://openalex.org/keywords/drug-tolerability","display_name":"drug tolerability","score":0.7699999809265137},{"id":"https://openalex.org/keywords/nausea","display_name":"nausea","score":0.9340000152587891},{"id":"https://openalex.org/keywords/ssri-antidepressants","display_name":"SSRI antidepressants","score":0.6710000038146973},{"id":"https://openalex.org/keywords/antidepressant-side-effects","display_name":"antidepressant side effects","score":0.4620000123977661},{"id":"https://openalex.org/keywords/treatment-discontinuation","display_name":"treatment discontinuation","score":0.3700000047683716}],"concepts":[{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.7582907676696777},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.7233529686927795},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6950801610946655},{"id":"https://openalex.org/C2780580376","wikidata":"https://www.wikidata.org/wiki/Q186889","display_name":"Nausea","level":2,"score":0.5764583945274353},{"id":"https://openalex.org/C2776214587","wikidata":"https://www.wikidata.org/wiki/Q3430227","display_name":"Vasomotor","level":2,"score":0.44903987646102905},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4254756271839142},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.22670823335647583},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.0},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D000069468","descriptor_name":"Desvenlafaxine Succinate","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D003511","descriptor_name":"Cyclohexanols","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D003511","descriptor_name":"Cyclohexanols","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D003511","descriptor_name":"Cyclohexanols","qualifier_ui":"Q000592","qualifier_name":"standards","is_major_topic":false},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004311","descriptor_name":"Double-Blind Method","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009325","descriptor_name":"Nausea","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":false},{"descriptor_ui":"D009325","descriptor_name":"Nausea","qualifier_ui":"Q000453","qualifier_name":"epidemiology","is_major_topic":false},{"descriptor_ui":"D014179","descriptor_name":"Neurotransmitter Uptake Inhibitors","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D014179","descriptor_name":"Neurotransmitter Uptake Inhibitors","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D014179","descriptor_name":"Neurotransmitter Uptake Inhibitors","qualifier_ui":"Q000592","qualifier_name":"standards","is_major_topic":false},{"descriptor_ui":"D014666","descriptor_name":"Vasomotor System","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":true},{"descriptor_ui":"D017060","descriptor_name":"Patient Satisfaction","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017698","descriptor_name":"Postmenopause","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D019584","descriptor_name":"Hot Flashes","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.1089/jwh.2011.2764","doi":"https://doi.org/10.1089/jwh.2011.2764","is_oa":false,"landing_page_url":"https://doi.org/10.1089/jwh.2011.2764","pdf_url":null,"source":{"id":"https://openalex.org/S191117624","display_name":"Journal of Women s Health","issn_l":"1059-7115","issn":["1059-7115","1540-9996","1931-843X","2168-7668"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320443","host_organization_name":"Mary Ann Liebert, Inc.","host_organization_lineage":["https://openalex.org/P4310320443","https://openalex.org/P4310320017"],"host_organization_lineage_names":["Mary Ann Liebert, Inc.","SAGE Publishing"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Women's Health","raw_type":"journal-article"},{"id":"pmid:22032759","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/22032759","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of women's health (2002)","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.9940000176429749}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":17,"referenced_works":["https://openalex.org/W1977708183","https://openalex.org/W1985458017","https://openalex.org/W1999257848","https://openalex.org/W2004593633","https://openalex.org/W2019340572","https://openalex.org/W2022191212","https://openalex.org/W2032187519","https://openalex.org/W2047166790","https://openalex.org/W2047218172","https://openalex.org/W2053782164","https://openalex.org/W2089361437","https://openalex.org/W2149671999","https://openalex.org/W2153332125","https://openalex.org/W2164350210","https://openalex.org/W2169078759","https://openalex.org/W2250088909","https://openalex.org/W4245377097"],"related_works":["https://openalex.org/W2071676971","https://openalex.org/W2004593633","https://openalex.org/W1985458017","https://openalex.org/W2135613526","https://openalex.org/W2032187519","https://openalex.org/W2083296605","https://openalex.org/W1991433627","https://openalex.org/W2008426008","https://openalex.org/W1994039933","https://openalex.org/W2069308710"],"abstract_inverted_index":{"OBJECTIVE:":[0],"To":[1],"determine":[2],"whether":[3],"titrating":[4],"up":[5],"and":[6,109,112,122,136,147,173],"tapering":[7],"down":[8],"of":[9,107,219,229,240],"desvenlafaxine":[10,13,33,38,41,52,59,73,81,91,132,161,197,230,241,253],"(administered":[11],"as":[12],"succinate)":[14],"improves":[15],"its":[16],"tolerability":[17,228],"in":[18,233],"postmenopausal":[19,234],"women":[20,235],"with":[21,236],"vasomotor":[22],"symptoms":[23],"(VMS).":[24],"METHODS:":[25],"In":[26,65],"the":[27,66,103,131,187,196,216,220],"1-week":[28],"titration":[29,140,144],"phase,":[30,69],"participants":[31,70],"received":[32,57,71],"100":[34,60,231],"mg/d":[35,43,48,61,75,83,86,93,134,138,170,232],"(no":[36],"titration),":[37],"50":[39,47,74,82,92,137,162,174,198,210,242,254],"mg/d,":[40],"25":[42,53,85,133],"(4":[44],"days)":[45],"then":[46,56,76,84],"(3":[49],"days),":[50],"or":[51,90,244,252],"mg/d.":[54],"Participants":[55],"open-label":[58],"for":[62,130,160,195],"15":[63],"weeks.":[64],"2-week":[67],"taper":[68,119,151,178,182,203,221,260],"placebo,":[72],"placebo":[77],"(7":[78,87],"days":[79,88],"each),":[80,89],"every":[94,164,212,257],"other":[95,165,213,258],"day.":[96],"Primary":[97],"endpoints":[98],"included":[99],"nausea":[100],"incidence":[101,126],"during":[102],"first":[104],"2":[105],"weeks":[106,120],"treatment":[108],"Discontinuation-Emergent":[110],"Signs":[111],"Symptoms":[113],"(DESS)":[114],"Checklist":[115],"total":[116,190],"scores":[117,156],"after":[118],"1":[121],"2.":[123],"RESULTS:":[124],"Nausea":[125],"was":[127,192,215],"significantly":[128,158,193],"lower":[129,159],"(19%)":[135],"(22.6%)":[139],"regimens":[141,179,225,239],"vs.":[142,180,201,205],"no":[143,181,202],"(35.2%;":[145],"p=0.004":[146],"p=0.035,":[148],"respectively).":[149],"At":[150,184],"week":[152,185],"1,":[153],"mean":[154,188],"DESS":[155,189],"were":[157,246],"mg":[163,211,255],"day":[166,214,259],"(2.26,":[167],"p<0.001),":[168,172],"50/25":[169],"(2.28,":[171],"mg/d-placebo":[175,199,243],"(1.84,":[176],"p<0.001)":[177],"(7.07).":[183],"2,":[186],"score":[191],"higher":[194],"regimen":[200],"(4.46":[204],"2.44,":[206],"respectively;":[207],"p=0.009).":[208],"Desvenlafaxine":[209],"least":[217],"tolerated":[218,248],"regimens.":[222],"CONCLUSIONS:":[223],"Titration":[224],"may":[226],"improve":[227],"VMS.":[237],"Taper":[238],"50/25-mg/d,":[245],"better":[247],"than":[249],"abrupt":[250],"discontinuation":[251],"given":[256],"regimen.":[261]},"counts_by_year":[{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":3},{"year":2021,"cited_by_count":2},{"year":2020,"cited_by_count":2},{"year":2019,"cited_by_count":2},{"year":2018,"cited_by_count":2},{"year":2015,"cited_by_count":3},{"year":2014,"cited_by_count":2},{"year":2013,"cited_by_count":2},{"year":2012,"cited_by_count":2}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}